Capital International Sarl Purchases 46,052 Shares of Amgen Inc. $AMGN

Key Points

• Capital International Sarl raised its stake in Amgen by 58.2%, buying an additional 46,052 shares to hold 125,120 shares valued at about $35.31 million at quarter-end.
• Amgen beat quarterly expectations with EPS of $5.29 (vs. $4.76 consensus) and revenue of $9.87 billion, and set FY 2026 guidance of 21.60–23.00 EPS.
• The company declared a quarterly dividend of $2.52 (annualized $10.08) with an ex-dividend date of May 15 and a yield of roughly 2.7%.

Capital International Sarl raised its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 58.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 125,120 shares of the medical research company's stock after acquiring an additional 46,052 shares during the period. Capital International Sarl's holdings in Amgen were worth $35,309,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in the business. Evelyn Partners Investment Management LLP purchased a new position in Amgen in the 2nd quarter worth $32,000. Howard Hughes Medical Institute purchased a new stake in Amgen during the 2nd quarter valued at $32,000. Cloud Capital Management LLC purchased a new stake in shares of Amgen during the third quarter worth about $34,000. AXS Investments LLC bought a new stake in shares of Amgen in the 3rd quarter worth approximately $42,000. Finally, Winnow Wealth LLC purchased a new stake in Amgen in the third quarter worth $47,000. Hedge funds and other institutional investors own 76.50% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have commented on AMGN. Citigroup upped their price objective on shares of Amgen from $315.00 to $345.00 and gave the stock a "neutral" rating in a report on Wednesday, February 4th. Sanford C. Bernstein downgraded shares of Amgen from an "outperform" rating to a "market perform" rating and set a $335.00 price target for the company. in a research note on Tuesday, January 20th. Cantor Fitzgerald raised their price objective on Amgen from $315.00 to $350.00 and gave the company a "neutral" rating in a research report on Wednesday, February 4th. Morgan Stanley boosted their target price on Amgen from $304.00 to $309.00 and gave the stock an "equal weight" rating in a report on Wednesday, February 4th. Finally, Wells Fargo & Company raised their price target on shares of Amgen from $325.00 to $375.00 and gave the company an "equal weight" rating in a research report on Thursday, February 19th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, twelve have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $354.17.

Amgen Trading Up 2.0%

Shares of Amgen stock opened at $376.97 on Tuesday. Amgen Inc. has a 1-year low of $261.43 and a 1-year high of $391.29. The company's fifty day simple moving average is $354.21 and its 200-day simple moving average is $323.38. The stock has a market capitalization of $203.21 billion, a PE ratio of 26.49, a P/E/G ratio of 3.67 and a beta of 0.45. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90.

Amgen (NASDAQ:AMGN - Get Free Report) last released its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company had revenue of $9.87 billion during the quarter, compared to analyst estimates of $9.46 billion. During the same period in the prior year, the firm posted $5.31 EPS. The firm's quarterly revenue was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, equities analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be issued a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date is Friday, May 15th. Amgen's payout ratio is currently 70.84%.

Amgen Company Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.